Related Experiment Video
Updated: Jun 1, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
What options are available when considering starting insulin: premix or basal?
1North Broward Diabetes Center, Pompano Beach, Florida 33073, USA. diabetescontrol@aol.com
Diabetes Technology & Therapeutics
|June 15, 2011
Summary
Early insulin initiation in type 2 diabetes is crucial for preventing complications. Basal insulin offers advantages over premixed insulin due to lower hypoglycemia and weight gain risks.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Intensive therapy in diabetes prevents long-term complications.
- Insulin initiation is often delayed in type 2 diabetes (T2D) despite evidence.
- Barriers include cost, hypoglycemia risk, convenience, and weight gain concerns.
Purpose of the Study:
- To compare once-daily basal insulin versus twice-daily premix insulin for initiating treatment in T2D.
- To evaluate efficacy and safety profiles of different insulin starter regimens.
- To inform optimal insulin initiation strategies tailored to individual patient needs.
Main Methods:
- Review of studies comparing basal insulin and premixed insulin regimens.
- Analysis of glycemic control, hypoglycemia rates, and weight changes.
- Consideration of patient-specific variables influencing treatment efficacy.
Main Results:
- Glycemic control is comparable between basal and premixed insulin regimens.
- Basal insulin demonstrates lower rates of hypoglycemia and weight gain.
- Basal insulin offers simplicity and convenience for initial therapy.
Conclusions:
- Once-daily basal insulin is a preferred first-line starter regimen for T2D patients failing oral agents.
- Individual patient factors necessitate tailored insulin treatment plans.
- Optimizing insulin initiation timing and regimen choice is key for managing T2D.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...